Furosoral

Quick links to important sections

Furosoral

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Furosoral

Quick Facts

Property Description
Active Ingredient Furosemide
Common Oral Form Tablet or Oral Solution
Pharmacological Class Loop Diuretic
General Purpose To manage fluid retention (edema)
Origin Synthetic Compound

What Type of Medicine is Furosoral?

Furosoral is a recognized trade name for a medication whose active component is the generic substance furosemide, classified as a powerful loop diuretic. Furosemide is utilized for its clinical effectiveness in managing fluid retention. This medication is used because its therapeutic effectiveness in managing fluid buildup is supported by clinical practice.

Furosoral belongs to a class of drugs that help the body manage fluid balance by increasing the excretion of water and salt. The key therapeutic purpose of this medication is to relieve the physical discomfort and health risks associated with excess fluid buildup, known medically as edema. A typical use scenario for a medicine of this class is to help a person manage persistent swelling in the legs and ankles.


Furosoral: Composition and Form

Furosoral is most commonly supplied as an oral medication, typically in the form of a solid tablet or an oral solution for convenient use. The active ingredient, furosemide, is a completely synthetic compound, which means it is manufactured chemically rather than being extracted from natural sources. This synthetic origin ensures a consistent dosage and predictable therapeutic effect in every dose. This oral form is designed for non-invasive, day-to-day administration outside of a clinical setting.


Why is Furosoral Considered a Potent Diuretic?

Furosoral is considered potent because it has a powerful and rapid effect on the kidneys' ability to remove large amounts of salt and water from the body. The strong action of furosemide quickly reduces the amount of fluid in the body, which helps relieve symptoms of edema. The drug is efficient at easing swelling caused by excess fluid. Unlike milder diuretics, the drug acts directly on a crucial part of the kidney's filtering system. This targeted mechanism is designed to quickly stop the body from reclaiming necessary salts, leading to a significant and noticeable increase in urine volume. This efficient fluid removal is the key general benefit, helping to rapidly reduce swelling and pressure in the circulatory system.

Regulatory References

  1. Furosemide entry in the WHO Essential Medicines List
  2. WHO Essential Medicines List

What side effects are possible with Furosoral?

Possible Side Effects and Safety Information

Furosoral, which contains the active substance furosemide, has an official safety profile primarily defined by its potent action on fluid balance. The most frequently documented adverse reactions relate to fluid and electrolyte disturbances, which regulatory bodies classify as very common.

These effects include the officially noted occurrences of dehydration, hypovolaemia (reduced blood volume), and imbalances such as low potassium (hypokalaemia) and low sodium (hyponatraemia). As a direct result of volume reduction, decreased blood pressure is also a very common characteristic noted in official labeling.

Adverse effects are also categorized by the affected body system. For instance, Gastrointestinal effects like nausea and vomiting are uncommon, as are certain Dermatological reactions such as photosensitivity and rashes. Potential effects on the Ear and Labyrinth, including deafness (uncommon) and tinnitus (rare), are officially documented, with an increased risk noted in severe renal impairment.

Serious adverse reactions, though rare, are explicitly listed in regulatory documents. These include severe anaphylactic reactions, aplastic anaemia, and severe skin reactions such as Toxic Epidermal Necrolysis (TEN). Official safety notes highlight that older adults are at a higher documented risk of dehydration and associated thromboembolic events, while pre-existing hepatic impairment creates a risk of precipitating hepatic encephalopathy.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information for Furosoral

Overdose of Furosoral (furosemide) primarily results from an exaggerated diuresis leading to the excessive loss of body fluid and electrolytes, according to government regulatory documents.

Immediate medical attention must be sought if an overdose is suspected or if severe signs of volume depletion occur. Seek immediate medical advice or contact emergency services if more than the recommended dose is taken.


Documented Overdose Manifestations

Item Official Regulatory Statement/Entity
Principal Signs Hypotension, dehydration, and blood volume reduction (hypovolemia).
Biochemical Findings Severe electrolyte imbalance, including hypokalemia and hypochloremic alkalosis.
Severe Outcomes Circulatory collapse, and the risk of vascular thrombosis and embolism are documented.

Supportive Treatment and Specific Risks

Treatment of overdosage is explicitly symptomatic and supportive, centered on the immediate replacement of excessive fluid and electrolyte losses. No specific antidote is known for furosemide overdose. Frequent monitoring of serum electrolytes and blood pressure is required during management.

Population-specific risks are noted for elderly patients, who are particularly susceptible to severe circulatory effects, and for patients with hepatic cirrhosis, where sudden fluid shifts risk precipitating hepatic coma.

Therapeutic Uses of Furosoral

What Furosoral Treats: Main Uses and Benefits

Furosoral, which contains furosemide, is generally used as a diuretic in the treatment of edema, or excess fluid accumulation. It is used to manage the symptoms related to systemic imbalance that cause fluid retention across several major disease areas. The primary role of the medication is to provide supportive relief in conditions presenting with systemic or localized discomfort from fluid retention.

The main therapeutic uses are relevant for easing symptoms in conditions characterized by periods of heightened symptoms, such as edema associated with congestive heart failure, liver cirrhosis, renal disease, and the management of elevated systemic vascular pressure (hypertension). The drug is applied across domains where additional symptomatic support is needed to address peripheral fluid swelling and generalized volume overload.

Quick Fact: Relief for Swelling and Fluid Overload

The therapeutic benefit is relevant for easing symptoms related to physical discomfort from excess fluid, which contributes to improved comfort and assists with maintaining functional stability during periods of pronounced swelling.

Regulatory References

  1. NIH DailyMed Label Information

Eligibility and Restrictions for Use

Who can and cannot use Furosoral?

Official regulatory documents define specific population eligibility and non-eligibility rules for Furosoral (Furosemide). Eligibility is determined by age, physiological state, and underlying comorbidities.

Contraindicated Populations

Furosoral is contraindicated and must not be used by patients with anuria (complete lack of urine production), known hypersensitivity to furosemide, or those experiencing severe hypokalaemia or hyponatraemia (low potassium or sodium). Use is also prohibited in patients who are in a comatose or pre-comatose state due to hepatic encephalopathy, and for women who are breastfeeding.

Age and Condition-Based Restrictions

Adults and pediatric patients are the populations eligible for edema treatment. Use in pregnant women is restricted and is only permitted for compelling medical reasons, not routine use. Caution is required for geriatric patients due to the risk of dehydration, and for preterm infants due to the risk of kidney stone formation.

Patients with severe renal impairment may need to discontinue the medicine if increasing azotemia occurs. Use is also restricted in patients with severe hepatic cirrhosis and those with existing hypovolemia or dehydration, which must be corrected prior to therapy.

What should I know about interactions with other medicines?

Furosoral, which contains furosemide, has officially documented interaction patterns primarily concerning additive effects and altered drug clearance, as stated in regulatory labels.

Contraindicated and Avoided Combinations

Regulatory documents state that co-administration with Ethacrynic acid is generally non-recommended due to the risk of additive ototoxicity (hearing damage). The combination with aminoglycoside antibiotics should also be avoided where possible because of a heightened ototoxicity risk, which is increased further in patients with severe renal impairment or hypoproteinemia. Intravenous Furosoral must not be administered within 24 hours of Chloral hydrate.

Pharmacokinetic and Pharmacodynamic Interactions

Combining Furosoral with ACE inhibitors or ARBs is documented to carry a risk for severe hypotension and deterioration in renal function. The medication also reduces the renal clearance of Lithium, officially resulting in a high potential for lithium toxicity. Furosoral may have additive effects in lowering blood pressure when taken with alcohol (ethanol) or other antihypertensive agents. Corticosteroids and large amounts of licorice pose an additive risk for hypokalemia (low potassium levels).

Administration Timing Rules

To prevent reduced absorption and loss of efficacy, the regulatory label establishes specific timing requirements for certain combinations. Co-administration with Sucralfate must be separated by at least two hours. Similarly, bile acid sequestrants like Colestyramine require a separation of two to three hours.

Mechanism of Action

Core Mechanism: Ion Transport Inhibition in the Kidney

Furosoral's primary action involves acting as an inhibitor of the Na^+–K^+–2Cl^- cotransporter (NKCC2) found exclusively in the kidney's thick ascending limb. This biological target is essential for the reabsorption of sodium, potassium, and chloride ions . By blocking this specific transport system, the drug prevents these ions and the water that follows them from being reclaimed by the body, thus initiating the mechanistic cascade that increases the volume of fluid delivered to the collecting ducts.


Physiological Result: Fluid Volume and Vascular Modulation

The inhibition of ion reabsorption increases the amount of salt and water expelled from the body, leading to a decrease in total circulating blood volume. Furthermore, the drug’s mechanism also causes a relaxation and widening of certain blood vessels by influencing local signaling molecules. These combined physiological consequences—reduced volume and altered vascular tone—are central to the drug's overall profile, resulting in a reduction of fluid volume and pressure in the systemic circulation.

Dosage and Administration Information

Furosoral, whose active ingredient is furosemide, is approved for administration via oral (tablet or solution), intravenous (IV), intramuscular (IM), and subcutaneous (SC) routes. The parenteral routes (IV/IM/SC) are generally reserved for acute clinical settings and should be replaced with the oral form as soon as practical for continued management.

The standard adult initial oral dose typically ranges from 20 mg to 80 mg once daily. Dosing is adaptable: the medicine may be used once daily, twice daily, or on an intermittent/cyclic schedule, such as on alternate days or two to four consecutive days per week. The maximum daily dose for severe, edematous conditions is noted to be up to 600 mg.

For proper oral use, the dose is commonly taken early in the day, usually before 4 PM, to avoid nocturnal diuresis. Although it may be taken with or without food, it is sometimes recommended to take it on an empty stomach for optimal effect. The IV injection must be administered slowly over one to two minutes, and the intake of Furosoral must be separated from sucralfate by at least two hours to prevent reduced absorption. Population-specific rules include starting older adults with a lower initial dose, such as 20 mg, and calculating pediatric doses based on body weight.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Furosoral


Evidence for Fluid Management in Congestive Heart Failure

Research for Furosoral in the context of heart failure edema has been conducted using Randomized Controlled Trials (RCTs) and larger observational settings. Researchers monitored outcomes related to systemic or functional imbalance, such as how fluid content in the body changes and how often re-hospitalization was recorded in the observed populations. Studies monitored changes in measurements like urine output and total fluid content, describing patterns observed shortly after Furosoral was administered. Despite this, the consistency of long-term outcomes, such as survival measurements when compared directly with alternative loop diuretics, is still being examined.


Research for Edema Associated with Kidney Disease

The research explored Furosoral's use in conditions involving physiological strain or stress due to kidney disease. This evidence comes from both RCTs and meta-analyses that specifically focused on outcomes related to systemic or functional imbalance. Studies report how symptoms evolved in the observed populations, frequently describing rapid fluid clearance and noticeable short-term changes in urine volume. However, research exploring Furosoral's association with influencing critical, long-term outcomes, such as mortality or the need for dialysis, has reported inconsistent findings, meaning the certainty remains low. Research is ongoing to establish the optimal dose studied in cases of severe renal impairment.


Evidence in Liver Cirrhosis and Fluid Accumulation

Research has explored Furosoral's use in managing fluid accumulation (ascites) and swelling in patients with liver cirrhosis. The research primarily consists of RCTs where Furosoral was almost always applied in combination with a different class of diuretic. Studies examined outcomes related to systemic or functional imbalance by measuring changes in body weight and abdominal size. Because most trials assessed the combination treatment, evidence defining the independent effect of Furosoral alone is limited.


Studies Addressing Elevated Blood Pressure

Research has explored Furosoral’s use in conditions involving physiological strain or stress due to elevated blood pressure (hypertension). This area of evidence includes systematic reviews and smaller RCTs. Studies report patterns related to changes in measured blood pressure, especially in populations that also had high fluid volume. Large-scale, long-duration RCTs designed to assess Furosoral as a single agent for uncomplicated essential hypertension are lacking.


What Is Still Uncertain and Research Gaps

Overall, the evidence highlights what is known, and what is still uncertain. Certainty remains low for the long-term effects related to major clinical outcomes, such as patient survival or the need for dialysis in some settings. Findings were mixed regarding the optimal strategies for administering the medication. Furthermore, the evidence base describes gaps related to specific patient groups, such as those with diuretic resistance, and the follow-up durations were limited in many key studies.

Key Studies & References

  1. Label: FUROSEMIDE tablet - DailyMed
  2. Diagnosis, Evaluation and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome | AASLD Practice Guidance

Frequently Asked Questions (FAQ)

Common questions about Furosoral (FAQ)


Q: How quickly does Furosoral start to work?

A: According to the official product information, the onset of the increase in urine output typically begins within one hour of taking an oral dose. The maximum effect is usually reached within the first or second hour after administration. The onset of effect is generally described as being rapid.


Q: Does Furosoral interact with common pain relievers like ibuprofen?

A: Regulatory documents state that patients using high doses of certain pain relievers, specifically those known as salicylates, may experience increased toxicity if taken with Furosoral. Official patient-facing warnings for non-salicylate pain relievers like ibuprofen are generally not detailed as a class, but official labels emphasize the need for assessment of all concurrent therapies.


Q: Does taking Furosoral make you sleepy?

A: Official documentation lists drowsiness as a possible symptom. This effect is often described as being associated with changes in the body’s fluid or electrolyte balance, which is the key mechanism of Furosoral.


Q: What should be done if Furosoral is accidentally taken too much?

A: Regulatory warnings state that taking the drug in amounts greater than prescribed can lead to profound diuresis (excessive urine production). This can result in the body losing too much water and essential minerals (electrolyte depletion), which is a situation that requires careful medical supervision and management.


Q: Does Furosoral need to be protected from light or moisture?

A: Official storage instructions for the medicine generally state that the tablets should be protected from light. The medicine is generally stored at a controlled room temperature to maintain product stability.


Q: Can Furosoral be taken alongside antacids?

A: The regulatory label establishes specific rules for administration timing with certain other medications. For example, specific drugs like sucralfate and bile acid sequestrants (which can be used for similar purposes as antacids) must be taken at least two hours apart from Furosoral to avoid the loss of effect.


Q: How long after stopping Furosoral do the effects wear off?

A: The primary fluid-removing effect following an oral dose typically lasts for about six to eight hours. The time it takes for half of the drug to be eliminated from the body (the half-life) is approximately two hours.


Q: Is Furosoral available as a generic medicine?

A: Yes, the active ingredient in Furosoral, which is furosemide, is widely available as a generic medication. The generic form is approved and regulated by health authorities.


Q: Can Furosoral be used by people with kidney problems?

A: Furosoral is officially indicated for managing fluid retention (edema) that is associated with renal disease (kidney problems). Regulatory warnings note that the medicine is used with caution, and that it may need to be discontinued if progressive renal disease occurs during treatment.


Q: Is Furosoral safe for elderly patients?

A: Official warnings note that older adults have a higher documented risk of excessive fluid loss (diuresis) and dehydration. Official guidance notes that dose selection for older adults typically involves starting at a lower dosage.


Q: Can Furosoral cause changes in mood or anxiety?

A: Regulatory documents list restlessness as a potential symptom related to the Central Nervous System. This effect may be observed in connection with significant changes in the body's fluid and mineral balance caused by the medicine.


Q: Will Furosoral show up on a standard drug test?

A: The active ingredient, furosemide, is sometimes identified in specific drug-testing collection systems mentioned in regulatory documentation. This indicates the drug's potential presence or detection in some screenings.


Q: Has Furosoral been studied in people with liver disease?

A: Yes, the drug is officially indicated for treating fluid retention associated with cirrhosis of the liver. Official warnings note that sudden fluid changes in those with cirrhosis carry a risk of precipitating hepatic coma.


Q: Does Furosoral need to be taken at the same time every day?

A: The official administration instructions describe the dose as a single dose that can be administered once daily, twice daily, or on an intermittent schedule. This means the specific timing is based on the prescribed regimen, rather than a fixed mandatory clock time every day.


Q: Can Furosoral cause changes in blood sugar levels?

A: Official warnings state that Furosoral may increase blood glucose levels and can affect tests related to glucose tolerance. There have been rare reports of the precipitation of diabetes mellitus.


Q: Is Furosoral known to cause headaches?

A: Yes, headache is listed as one of the possible Central Nervous System reactions in the official adverse reactions section of the regulatory documents.


Q: Are there any limitations on physical activity while using Furosoral?

A: The official label notes that orthostatic hypotension (feeling dizzy or lightheaded upon quickly standing up) may occur. Patients are advised that this can usually be minimized by changing body position slowly.

How should Furosoral be stored and disposed of?

Storage and Disposal of Furosoral (Furosemide)

This section outlines the mandatory storage and disposal rules for Furosoral tablets as documented in official regulatory labeling.

Storage Requirements

Furosoral tablets must be stored at a temperature not exceeding 25°C and must be protected from light to maintain product stability. As a critical safety rule, the medication must always be stored out of the sight and reach of children.

Storage Condition Requirement
Temperature Limit Do not store above 25°C.
Protection Protect from light.

Stability and Handling

The product has a shelf life of four years as packaged for sale. If a tablet is broken, the unused part must be returned to the open blister space and box immediately and used within 3 days of being broken.

Disposal Instructions

Unused or expired Furosoral must be disposed of in accordance with local requirements. The medicine must not be discarded via wastewater or household waste to prevent environmental contamination, as explicitly stated in the regulatory documentation.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Furosoral found in:

A-Z Index: